Clearmind Medicine Inc. (CMND)
NASDAQ: CMND · Real-Time Price · USD
1.020
+0.060 (6.23%)
At close: Aug 7, 2025, 4:00 PM
1.020
0.00 (0.00%)
Pre-market: Aug 8, 2025, 8:37 AM EDT

Company Description

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems.

It develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression.

The company develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder.

In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post traumatic stress disorder and other health conditions.

The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021.

The company was incorporated in 2017 and is based in Vancouver, Canada.

Clearmind Medicine Inc.
Clearmind Medicine logo
CountryCanada
Founded2017
IndustryBiotechnology
SectorHealthcare
Employees4
CEOAdi Zuloff-Shani

Contact Details

Address:
1220 West 6th Avenue, Suite 101
Vancouver, BC V6H 1A5
Canada
Phone973 536 1016
Websiteclearmindmedicine.com

Stock Details

Ticker SymbolCMND
ExchangeNASDAQ
Fiscal YearNovember - October
Reporting CurrencyUSD
CIK Code0001892500
ISIN NumberCA1850534027
SIC Code2834

Key Executives

NamePosition
Dr. Adi Zuloff-Shani Ph.D.Chief Executive Officer
Alan Mark Rootenberg B.Com., B.Comm, C.A., CPAChief Financial Officer
Prof. Mark Haden M.S.W.Vice President of Business Development
Mylene TouboulAccounting Manager
Adi VaronController

Latest SEC Filings

DateTypeTitle
Aug 7, 20256-KReport of foreign issuer
Aug 5, 20256-KReport of foreign issuer
Jul 30, 20256-KReport of foreign issuer
Jul 29, 20256-KReport of foreign issuer
Jul 15, 20256-KReport of foreign issuer
Jul 3, 2025SCHEDULE 13G/AFiling
Jul 3, 20256-KReport of foreign issuer
Jun 30, 20256-KReport of foreign issuer
Jun 27, 20256-KReport of foreign issuer
Jun 23, 20256-KReport of foreign issuer